Our last year paper provide further insight to this https://t.co/FEG8P6fRer
RT @KynTherapeutics: #ICYMI Our CEO @markgmanfredi, @LIMR_'s George Prendergast and other experts talk next steps in #IDO inhibition after…
RT @KynTherapeutics: #ICYMI Our CEO @markgmanfredi, @LIMR_'s George Prendergast and other experts talk next steps in #IDO inhibition after…
#ICYMI Our CEO @markgmanfredi, @LIMR_'s George Prendergast and other experts talk next steps in #IDO inhibition after the ECHO-301 trial in a recent publication from Seminars in #Immunopathology. More here: https://t.co/GqVHpXiMSN #immunotherapy https://t.
RT @ZakhariaYousef: Thoughts and lessons learned form the melanoma Epacadostat ECHO-301 trial, now online @MelanomaIowa @markgmanfredi @mmp…
@ZakhariaYousef Apologies Yousef!!! BTW - great commentary on #ECHO301 by Muller, @markgmanfredi, you and Prendergast! https://t.co/HdwqqD6QOm
Thoughts and lessons learned form the melanoma Epacadostat ECHO-301 trial, now online @MelanomaIowa @markgmanfredi @mmpmelanoma @LIMR_ @Incyte https://t.co/RqzUcTyXfH https://t.co/GB20wzNxr5
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. https://t.co/2KWDC1LtF2
RT @KynTherapeutics: Today in Seminars in #Immunopathology: a new paper coauthored by our CEO @markgmanfredi and @LIMR_'s George Prendergas…
Today in Seminars in #Immunopathology: a new paper coauthored by our CEO @markgmanfredi and @LIMR_'s George Prendergast discussing the future of #immunotherapy research beyond the ECHO-301 trial. Read the full paper here: https://t.co/GqVHpXiMSN #immunomet